Drug delivery by red blood cells

Drug delivery is a growing field of interdisciplinary activities that combine the use of new materials with the biochemical properties of selected drugs, with the aim of improving their therapeutic action and reducing their toxicity. In few cases, proper medical devices have been also realized to implement new drug delivery modalities. In this article, we have summarized available information and our experience on the use of autologous Red Blood Cells as carriers for drugs to be released within the vascular system. This is not a comprehensive review, but it focusses on the mechanisms that are available to distribute drugs in circulation by carrier red blood cells and provide illustrative examples on how this is currently obtained. We have not included a summary of clinical data collected in recent years using this technology but simply provided proper references for the interested readers. Finally, a special attention is devoted to the possibility of entrapping, into autologous red blood cells, recombinant drug‐binding proteins. This new strategy is opening the way at a new modality to influence the vascular distribution of drugs by realizing a dynamic circulating container (the engineered red cell) capable of reversible binding and transportation of one or more drugs of interest selected on the bases of the red cell entrapped target proteins. This new modality is not yet fully developed and explored but will certainly provide a technical solution to the problem of stabilizing drug concentration in circulation improving drug efficacy and reducing drug toxicity. © 2011 IUBMB IUBMB Life, 2011

[1]  Vladimir R Muzykantov,et al.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes , 2003, Nature Biotechnology.

[2]  C Lizano,et al.  In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure. , 1998, Biochimica et biophysica acta.

[3]  Mehrdad Hamidi,et al.  Applications of carrier erythrocytes in delivery of biopharmaceuticals. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[4]  J. Deloach Dialysis method for entrapment of proteins into resealed red blood cells. , 1987, Methods in Enzymology.

[5]  R. Desnick,et al.  Enzyme therapy. V. In vivo fate of erythrocyte-entrapped beta-glucuronidase in beta-glucuronidase-deficient mice. , 1975, Pediatric Research.

[6]  J. L. Way,et al.  In vivo studies on rhodanese encapsulation in mouse carrier erythrocytes. , 1991, Toxicology and applied pharmacology.

[7]  H. Simmonds,et al.  Carrier erythrocyte entrapped adenosine deaminase therapy in adenosine deaminase deficiency. , 2000, Advances in Experimental Medicine and Biology.

[8]  G. Rodriguez Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma. , 1994, Investigational new drugs.

[9]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[10]  M. Muqit,et al.  CARRIER ERYTHROCYTE ENTRAPPED THYMIDINE PHOSPHORYLASE THERAPY FOR MNGIE , 2008, Neurology.

[11]  Cheol Moon,et al.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[12]  S. Updike,et al.  Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences. , 1983, The Journal of laboratory and clinical medicine.

[13]  M. Pinilla,et al.  In vitro and in vivo study of glutamate dehydrogenase encapsulated into mouse erythrocytes by a hypotonic dialysis procedure. , 1999, Life sciences.

[14]  W J Jusko,et al.  Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Minnie Sarwal,et al.  Calcineurin Inhibitor Nephrotoxicity , 2012 .

[16]  M. Magnani,et al.  Cell-based drug delivery. , 2008, Advanced drug delivery reviews.

[17]  G. Damonte,et al.  Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. , 1996, Biochemical and biophysical research communications.

[18]  A. Andriulli,et al.  Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients—A Pilot Uncontrolled Study , 2005, The American Journal of Gastroenterology.

[19]  W. Satterfield,et al.  Intraperitoneal administration of carrier erythrocytes in dogs: an improved method for delivery of L‐asparaginase , 1990, Biotechnology and applied biochemistry.

[20]  S. Snyder,et al.  The 13-kD FK506 Binding Protein, FKBP13, Interacts with a Novel Homologue of the Erythrocyte Membrane Cytoskeletal Protein 4.1 , 1998, The Journal of cell biology.

[21]  L Bigi,et al.  Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.

[22]  N. Zaffaroni,et al.  Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines. , 2010, International journal of oncology.

[23]  Mauro Magnani,et al.  Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: case report. , 2006, Journal of pediatric gastroenterology and nutrition.

[24]  Nolan H. Sigal,et al.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin , 1989, Nature.

[25]  M. Magnani,et al.  Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[26]  A. Batlle,et al.  Enzyme replacement therapy in porphyrias--IV. First successful human clinical trial of delta-aminolevulinate dehydratase-loaded erythrocyte ghosts. , 1983, The International journal of biochemistry.

[27]  M. Magnani,et al.  Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity. , 1989, Biochemical and biophysical research communications.

[28]  J. L. Way,et al.  Erythrocytes as Drug Carriers in Medicine , 1997, Springer US.

[29]  R H Glew,et al.  Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Iwaki,et al.  Encapsulation of human urokinase in rabbit erythrocytes and its disposition in the circulation system in rabbits. , 1987, Journal of pharmacobio-dynamics.

[31]  E. Beutler,et al.  Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Broeckhoven,et al.  Hyperargininemia: the rat as a model for the human disease and the comparative response to enzyme replacement therapy with free arginase and arginase-loaded erythrocytes in vivo. , 1984, International Journal of Biochemistry.

[33]  S. Barik Immunophilins: for the love of proteins , 2006, Cellular and Molecular Life Sciences CMLS.

[34]  M. Laguerre,et al.  Acetaldehyde dehydrogenase-loaded erythrocytes as bioreactors for the removal of blood acetaldehyde. , 1989, Alcoholism, clinical and experimental research.

[35]  M Cutolo,et al.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data , 2005, Annals of the rheumatic diseases.

[36]  M. Magnani,et al.  Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes. , 1996, Biochimica et biophysica acta.

[37]  M. Laguerre,et al.  Erythrocytes as Carriers for L‐Asparaginase. Methodological and Mouse In‐vivo Studies , 1990, The Journal of pharmacy and pharmacology.

[38]  G. Damonte,et al.  Red Blood Cells as a Delivery System for AZT , 1995 .

[39]  B. Chabner Pharmacologic principles of cancer treatment , 1982 .

[40]  D. Atochin,et al.  Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator , 2008, Circulation.

[41]  H. Dengler,et al.  Characterization of cyclosporine a uptake in human erythrocytes , 2004, European Journal of Clinical Pharmacology.

[42]  B. Bax,et al.  In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol‐conjugated and native adenosine deaminase , 2000, British journal of haematology.

[43]  M. Magnani,et al.  Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation. , 1992, Advances in experimental medicine and biology.

[44]  M. Magnani,et al.  Red Blood Cells as a Glucocorticoids Delivery System , 1997 .

[45]  F. Aweeka,et al.  Drug Concentration Monitoring of Immunosuppressive Agents , 2000, BioDrugs.

[46]  M. Magnani,et al.  The Use of Resealed Erythrocytes as Carriers and Bioreactors , 1992, Advances in Experimental Medicine and Biology.

[47]  Gianluca Damonte,et al.  Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. , 2004, Blood cells, molecules & diseases.

[48]  이현주,et al.  ADRENOCORTICOTROPIC hormone. , 1951, Lancet.

[49]  J. L. Way,et al.  Encapsulation of phosphotriesterase within murine erythrocytes. , 1994, Toxicology and applied pharmacology.

[50]  J. Davison,et al.  Drug Safety Issues in Pregnancy Following Transplantation and Immunosuppression , 1998, Drug safety.

[51]  E. Zocchi,et al.  Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Vladimir R Muzykantov,et al.  Drug delivery by red blood cells: vascular carriers designed by mother nature , 2010, Expert opinion on drug delivery.

[53]  J. L. Way,et al.  Rhodanese and sodium thiosulfate encapsulated in mouse carrier erythrocytes. II. In vivo survivability and alterations in physiologic and morphologic characteristics. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[54]  G. Sudlow,et al.  Further characterization of specific drug binding sites on human serum albumin. , 1976, Molecular pharmacology.

[55]  L. Mchale,et al.  Encapsulation of the thrombolytic enzyme, brinase, in photosensitized erythrocytes: a novel thrombolytic system based on photodynamic activation. , 1994, Journal of photochemistry and photobiology. B, Biology.

[56]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[57]  R. Sheeladevi,et al.  Detoxification of formate by formate dehydrogenase-loaded erythrocytes and carbicarb in folate-deficient methanol-intoxicated rats. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[58]  Benjamin A. Shoemaker,et al.  Knowledge-based annotation of small molecule binding sites in proteins , 2010, BMC Bioinformatics.

[59]  Tipton Kf,et al.  The influence of enzyme concentration on the encapsulation of glutamate dehydrogenase and alcohol dehydrogenase in red blood cells , 1995, Biotechnology and applied biochemistry.

[60]  R. Kershner,et al.  Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. , 1996, Transplantation.

[61]  F. Aweeka,et al.  Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. , 2000, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[62]  P. Ind,et al.  A 9‐yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult‐type ADA deficiency , 2007, European journal of haematology.

[63]  A. Tanaka [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[64]  V. Muzykantov,et al.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[65]  D. Lewis,et al.  Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. , 1985, Biochemical pharmacology.

[66]  Gianluca Damonte,et al.  Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study , 2008, The American Journal of Gastroenterology.

[67]  R. Glew,et al.  Enzymatic degradation of uric acid by uricase-loaded human erythrocytes. , 1975, The Journal of clinical investigation.

[68]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[69]  X. Barril,et al.  Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.

[70]  M. Magnani,et al.  Long-term Treatment With Autologous Red Blood Cells Loaded With Dexamethasone 21–Phosphate in Pediatric Patients Affected by Steroid-dependent Crohn Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[71]  J. L. Way,et al.  Encapsulation of thiosulfate: cyanide sulfurtransferase by mouse erythrocytes. , 1986, Toxicology and applied pharmacology.

[72]  T. Philip,et al.  Tolerance Evaluation of L-asparaginase loaded in red blood cells , 1996, European Journal of Clinical Pharmacology.

[73]  B. Ryffel,et al.  Identification of cyclophilin as the erythrocyte ciclosporin-binding protein. , 1988, Biochimica et biophysica acta.